Multicentre Pilot Study of Dihydropyrimidine Dehydrogenase (DPD) Deficiency for Predicting Capecitabine Toxicity in Breast Cancer Patients.

Next Previous
Trial Profile

Multicentre Pilot Study of Dihydropyrimidine Dehydrogenase (DPD) Deficiency for Predicting Capecitabine Toxicity in Breast Cancer Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2015

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Acronyms DPD SEIN

    • Most Recent Events

    • 18 Aug 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top